Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 1/20 | 0.50 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 11/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14112297 | 0.88 | CSNK1D (0.50) | CSNK1DCSNK1G2IRAK4BTKEPHA2 | |
| SCHEMBL14112289 | 0.87 | CSNK1D (0.49) | CSNK1DCSNK1G2IRAK4BTKEPHA2 | |
| SCHEMBL14112290 | 0.85 | BTK (0.49) | CSNK1DCSNK1G2BTKPIK3CD | |
| SCHEMBL14112308 | 0.84 | CSNK1D (0.51) | CSNK1DCSNK1G2BTKPIK3CDCNR1 | |
| SCHEMBL14112314 | 0.84 | CSNK1D (0.51) | CSNK1DCSNK1G2BTKPIK3CDCNR1 | |
| SCHEMBL14112303 | 0.83 | CSNK1D (0.50) | CSNK1DCSNK1G2BTKPIK3CDCNR1 | |
| SCHEMBL14112294 | 0.82 | BTK (0.47) | CSNK1DCSNK1G2BTKCNR1 | |
| SCHEMBL14112309 | 0.82 | CSNK1D (0.49) | CSNK1DCSNK1G2BTKPIK3CDCNR1 | |
| SCHEMBL14112299 | 0.82 | CSNK1D (0.49) | CSNK1DCSNK1G2BTKPIK3CDCNR1 | |
| SCHEMBL14112291 | 0.82 | CSNK1D (0.49) | CSNK1DCSNK1G2BTKEPHA2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
| WO-2008060621-A2 | AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | CSNK1D 1339/4885CSNK1G2 1657/4885IRAK4 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.